CD226 anticorps (C-Term)

N° du produit ABIN5533743

L’anticorps Lapin Polyclonal anti-CD226 a été validé pour WB. Il convient pour détecter CD226 dans des échantillons de Humain.

Aperçu rapide pour CD226 anticorps (C-Term) (ABIN5533743)

Antigène: CD226

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CD226 est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-CD226 anticorps

Épitope: AA 307-335, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This CD226 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 307-335 amino acids from the C-terminal region of human CD226.

Isotype: Ig Fraction

Information d'application

Indications d'application: For WB starting dilution is: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur CD226

Antigène: CD226

Autre désignation: CD226

Sujet: CD226 is a glycoprotein expressed on the surface of NK cells, platelets, monocytes and a subset of T cells. It is a member of the Ig-superfamily containing 2 Ig-like domains of the V-set. The protein mediates cellular adhesion of platelets and megakaryocytic cells to vascular endothelial cells. The protein also plays a role in megakaryocytic cell maturation. [provided by RefSeq].

Poids moléculaire: 39 kDa

ID gène: 10666

UniProt: Q15762

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints